Autoimmunity BioSolutions

What Autoimmunity BioSolutions does

Autoimmunity BioSolutions (ABS) is a Houston-based preclinical biotechnology company developing precision immuno-corrective therapies that target the soluble Interleukin 7 Receptor (sIL7R) pathway to treat genetically defined autoimmune diseases. The company's core platform consists of proprietary anti-sIL7R monoclonal antibodies that selectively inhibit the soluble form of the IL7 receptor while sparing the canonical membrane-bound IL7R, thereby restoring immune homeostasis without inducing broad immunosuppression. This is complemented by antisense oligonucleotides (ASOs) as an alternative therapeutic modality and proprietary biomarker assays that measure sIL7R serum levels and the SNP rs6897932 genotype to identify responder populations.

ABS targets three lead indications: rheumatoid arthritis, lupus/lupus nephritis, and Type 1 Diabetes, each of which has approximately 50% non-response rates to current standard-of-care therapies and is associated with elevated sIL7R levels in the genetically defined risk population. The scientific foundation rests on extensive peer-reviewed literature, including foundational work by co-founder Dr. Gaddiel Galarza-Muñoz establishing sIL7R causality, and is reinforced by a Scientific Advisory Board that includes 1993 Nobel Laureate Sir Richard Roberts and National Academy of Sciences member Dr. Mariano A. Garcia-Blanco.

The company is privately held and pre-revenue, having raised $3.1 million in cumulative seed funding led by Eos BioInnovation, with additional participation from Independent Capital, Elmstead Partners, Alexandria Venture Investments, and NewTech Investment Holdings. Management includes CEO Eugene Williams (former SVP at Genzyme), CMO Dick Polisson (former Head of Translational Medicine at Sanofi-Genzyme), and CBO Jen Beachell (former Founding COO of Upstream Bio and VP at J&J). The business model is a preclinical asset-development play targeting future licensing or strategic partnerships with larger pharmaceutical companies for commercialization, with a secondary office in Cambridge, Massachusetts to access the Boston biotech ecosystem.

Name

Autoimmunity BioSolutions

Legal name

Autoimmunity BioSolutions

Website

https://abstherapeutics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Autoimmunity BioSolutions is a preclinical biotechnology company developing anti-sIL7R monoclonal antibodies, antisense oligonucleotides, and companion biomarker assays to treat genetically defined autoimmune diseases (rheumatoid arthritis, lupus, and Type 1 Diabetes) in patients unresponsive to standard of care.

Ownership category

akta.pro rank

Product category

Autoimmune Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (6215)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Immuno-corrective therapeutics
• Anti-sIL7R monoclonal antibodies
• Antisense oligonucleotide therapy
• Autoimmune disease biomarkers
• Precision immunology biotechnology

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-revenue Biotechnology R&D: Preclinical-stage biotechnology company with no commercial revenue. Currently funded by seed capital ($3.1M total) to advance preclinical development; future revenue expected from licensing/out-licensing, strategic partnerships, or eventual commercialization of immuno-corrective therapies and companion biomarker diagnostics.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Autoimmunity BioSolutions is a preclinical-stage biotechnology company developing a genetically-guided immuno-corrective therapy platform that targets the soluble Interleukin 7 Receptor (sIL7R) to treat autoimmune diseases. Its core pipeline consists of anti-sIL7R monoclonal antibodies, antisense oligonucleotides, and proprietary sIL7R biomarker assays intended to restore immune homeostasis in patients carrying the rs6897932 SNP, with lead indications in rheumatoid arthritis, lupus/lupus nephritis, and type 1 diabetes. The company is not yet commercializing any product and expects to monetize through future licensing or strategic partnerships with larger pharmaceutical companies.

Product overview

Autoimmunity BioSolutions (ABS) operates a single integrated immuno-corrective therapy platform rather than a portfolio of unrelated products. The platform targets genetically elevated soluble IL7 receptor (sIL7R), driven by the rs6897932 SNP, which is associated with more severe autoimmune disease and poor response to standard of care in roughly half of patients. Its core deliverable is the Anti-sIL7R Monoclonal Antibodies (mAbs) program, supported by Anti-sIL7R Antisense Oligonucleotides (ASOs) as a complementary therapeutic modality. Layered on top of these therapeutics are sIL7R Prognostic and Responder Biomarkers, which identify genetically defined responder populations both for ABS's own pipeline and for existing standards of care. The combined offering addresses rheumatoid arthritis, lupus/lupus nephritis, and Type 1 Diabetes as lead indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Anti-sIL7R Monoclonal Antibodies (mAbs) Proprietary monoclonal antibody therapeutic candidate that selectively inhibits soluble IL7R while sparing membrane-bound IL7R, designed to restore immune homeostasis in genetically defined autoimmune disease patients carrying the rs6897932 SNP without inducing broad immunosuppression. Being developed for licensing/partnering with larger pharmaceutical companies.
• Anti-sIL7R Antisense Oligonucleotides (ASOs) Oligonucleotide-based therapeutic candidates designed to lower sIL7R levels in patients carrying the rs6897932 SNP, complementing the monoclonal antibody program as part of ABS's portfolio of sIL7R-targeting immuno-corrective therapies.
• sIL7R Prognostic and Responder Biomarker Assays Proprietary diagnostic biomarker assays that measure sIL7R serum levels and rs6897932 SNP genotype to identify patients likely to respond to ABS's therapeutics and to existing standards of care, functioning as companion diagnostics for personalized immuno-corrective therapy.

Quantifiable outcome

• 56% of infliximab non-responders exhibited high sIL7R levels, vs only 15% of responders
• +4 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• ProMIS Neurosciences: Precision antibody developer led by ABS CEO Eugene Williams as Chair & Co-Founder. Uses a proprietary platform to generate antibodies selectively targeting disease-relevant protein conformations, paralleling ABS's approach of selectively targeting sIL7R while sparing the membrane-bound form.
• Dice Therapeutics (now Eli Lilly): Precision immunology company developing oral small molecules against intracellular protein-protein interactions in autoimmune disease, acquired by Eli Lilly for ~$2.4B. Comparable to ABS as a precision autoimmune platform with genetically/biology-defined responder hypotheses.
• Prometheus Biosciences (now Merck): Precision immunology company acquired by Merck for ~$10.8B for its IBD and autoimmune biologics pipeline with companion diagnostic strategy. Direct comparator for ABS's drug-plus-diagnostic precision autoimmune model.
• Pandion Therapeutics (now Merck): Autoimmune-focused biotech developing engineered biologics with tissue-selective immunomodulation, acquired by Merck for ~$1.85B. Comparable to ABS in targeting immune dysregulation with a precision-engineered therapeutic platform.
• AnaptysBio: Clinical-stage antibody development company with a pipeline in autoimmune and inflammatory disease (e.g., rosnilimab, anti-PD-1 agonist). Comparable therapeutic modality (antibodies) and autoimmune disease focus to ABS.
• Compass Therapeutics: Clinical-stage biotech developing antibody therapeutics in autoimmune/inflammation and oncology. Comparable as an antibody-platform biotech targeting immune-related diseases with multiple candidates.

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders with a focus on immunology/inflammation (e.g., IRAK4 degrader in autoimmune disease). Comparable immunology focus and modality innovation similar to ABS's anti-sIL7R + ASO approach.
• Arcturus Therapeutics: Late-stage clinical company developing oligonucleotide-based therapeutics (mRNA, siRNA, ASO) including programs in autoimmune disease such as lupus. Comparable modality to ABS's ASO arm targeting sIL7R.

Broad incumbents

• Horizon Therapeutics (now Amgen): Large specialty biopharma acquired by Amgen for ~$28B with a broad autoimmune/inflammation portfolio (e.g., Tepezza, Krystexxa). Comparable incumbent competitor targeting severe autoimmune patient populations that ABS's sIL7R therapy would also address.
• Sanofi (Dupixent franchise): Global biopharma with the leading franchise in autoimmune-driven inflammatory disease (Dupixent/ dupilumab, frexalimab). Key competitor in RA, lupus, and T1D-adjacent indications where ABS is advancing its lead program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autoimmunity BioSolutions